Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28620480 | 0.90 | ALDH1A1 (0.59) | ALDH1A1CYP2A6RXFP1CASP3SENP7 | |
| SCHEMBL9607472 | 0.90 | ALDH1A1 (0.58) | ALDH1A1CYP2A6RXFP1CASP3SENP7 | |
| SCHEMBL15258007 | 0.86 | ALDH1A1 (0.57) | ALDH1A1CYP2A6RXFP1NPC1RAB9A | |
| SCHEMBL21034959 | 0.81 | CYP11B1 (0.43) | ALDH1A1CYP2A6RXFP1NPC1RAB9A | |
| SCHEMBL28682644 | 0.80 | CYP11B1 (0.56) | ALDH1A1CYP2A6RXFP1CASP3SENP7 | |
| SCHEMBL30747787 | 0.80 | CYP11B1 (0.56) | ALDH1A1CYP2A6RXFP1CASP3SENP7 | |
| Formic Acid Methyl Ester SCHEMBL27958604 | 0.80 | RXFP1 (0.49) | ALDH1A1RXFP1CASP3SENP7SENP8 | |
| SCHEMBL17754087 | 0.79 | RXFP1 (0.54) | RXFP1CASP3SENP7SENP8SENP6 | |
| SCHEMBL6351 | 0.78 | ALDH1A1 (0.86) | ALDH1A1CYP2A6LMNAKDM4EMAPT | |
| SCHEMBL19214399 | 0.78 | ALDH1A1 (0.86) | ALDH1A1CYP2A6LMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111154115-B | Preparation method and application of binuclear Ir (III) metal-organic supermolecular cage-like compound | 大连理工大学 | 2021-09-21 | — | — | CN | claimed |
| CN-111154115-A | Preparation method and application of binuclear Ir (III) metal-organic supermolecular cage-like compound | 大连理工大学 | 2020-05-15 | — | — | CN | claimed |
| CN-111154115-B | Preparation method and application of binuclear Ir (III) metal-organic supermolecular cage-like compound | 大连理工大学 | 2021-09-21 | — | — | CN | disclosed |
| CN-111154115-A | Preparation method and application of binuclear Ir (III) metal-organic supermolecular cage-like compound | 大连理工大学 | 2020-05-15 | — | — | CN | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | ALDH1A1 2293/4885CYP2A6 582/4885RXFP1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.